AFX 001
Alternative Names: AFX-001Latest Information Update: 31 Mar 2023
At a glance
- Originator AffyXell Therapeutics
- Developer AffyXell Therapeutics; Avacta; Daewoong Pharmaceutical
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Graft-versus-host disease; Transplant rejection
Most Recent Events
- 27 Feb 2023 Preclinical trials in Graft-versus-host disease in South Korea (Parenteral), prior to February 2023 (Avacta pipeline, February 2023)
- 27 Feb 2023 Preclinical trials in Transplant rejection in South Korea (Parenteral), prior to February 2023 (Avacta pipeline, February 2023)
- 08 Jan 2020 Avacta and Daewoong Pharmaceutical agree to co-develop cell-therapies for Autoimmune disorders and inflammation